Comprehensive genomic profiling of triple-negative breast cancer metastases identifies role of PKD1 in immunotherapy resistance - PubMed
6 hours ago
- #Immunotherapy Resistance
- #Genomic Profiling
- #Breast Cancer
- Comprehensive genomic profiling of 296 metastatic triple-negative breast cancer (TNBC) samples identified 796 metastatic events across 18 organ sites.
- Polycystin-1 (PKD1) mutations were significantly enriched in metastatic lesions and associated with resistance to anti-PD-1 therapy.
- PKD1 mutations modulate the tumor immune microenvironment via C-C motif chemokine ligand 2 (CCL2), contributing to immunotherapy resistance.
- Targeting CCL2 could potentially reverse immunotherapy resistance in TNBC patients with PKD1 mutations.
- The study provides insights into tumor evolution and suggests a new therapeutic strategy for overcoming immunotherapy resistance.